Mylan, Roche reach deal over cancer drug

Litigation over Xeloda dismissed

PITTSBURGH — Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

Mylan announced Wednesday that it had entered a settlement and license agreement with Hoffmann La Roche resolving a patent infringement lawsuit over Xeloda (capecitabine) tablets, a drug used to treat breast and colorectal cancers that have spread to other parts of the body.

The litigation was dismissed Tuesday, though additional details of the deal were not disclosed, and it is still subject to review by the Department of Justice and the Federal Trade Commission.

Xeloda had sales of $570 million during the 12-month period ended in June, according to IMS Health.

Login or Register to post a comment.